(OAKVILLE, Ontario) February 22, 2022 – FORUS Therapeutics, a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer, today announced it has secured $2.5M CAD in growth capital...
FORUS Therapeutics a le plaisir d’annoncer la nomination de Marie-Josèphe Champagne au poste de liaison médicale scientifiques principale pour le Québec et l’Atlantique. Marie-Josèphe a plus de 18 ans d’expérience dans l’industrie pharmaceutique dans des rôles...
Despite all the global and local challenges; related and unrelated to the pandemic, 2021 has been a year of tremendous growth, progress and development at FORUS. We are excited about 2022 and look forward to fulfilling our mission by bringing innovative new medicines...
In recognition of this last day of September and the close of Blood Cancer Awareness Month, FORUS Therapeutics Inc. is pleased to announce that Health Canada has accepted for review the New Drug Submission (NDS) for once-weekly XPOVIO® (selinexor) in combination with...
FORUS Therapeutics is excited to introduce Kim Newhouse as the Senior Medical Manager. Recognized as a dedicated medical affairs business partner with a drive to deliver with excellence, Kim brings two decades of hematology/oncology launch experience in the Canadian...
We are thrilled to introduce Tracy Nagy as the Senior Medical Science Liaison for Central Canada. Tracy has dedicated her over 35-year career to patients in hematology/oncology including extensive experience as a MSL and as a Nurse Practitioner/Transplant Coordinator...
Recent Comments